Lumos Diagnostics Holdings (ASX:LDX) Total Liabilities: A$23.89 Mil (As of Dec. 2025)


ASX:LDX Lumos Diagnostics Holdings Ltd ASX:LDX
31 GF Score
Price A$0.11
GF Value A$0.02
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Lumos Diagnostics Holdings Total Liabilities?

Lumos Diagnostics Holdings ASX:LDX 31 Total Liabilities is A$23.89 Mil as of Dec. 2025. GuruFocus rates ASX:LDX with a GF Score™ of 31/100 and a GF Value™ of A$0.02 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Lumos Diagnostics Holdings's Total Liabilities for the quarter that ended in Dec. 2025 was A$23.89 Mil.

Lumos Diagnostics Holdings's quarterly Total Liabilities declined from Dec. 2024 (A$26.38 Mil) to Jun. 2025 (A$22.51 Mil) but then increased from Jun. 2025 (A$22.51 Mil) to Dec. 2025 (A$23.89 Mil).

Lumos Diagnostics Holdings's annual Total Liabilities increased from Jun. 2023 (A$23.72 Mil) to Jun. 2024 (A$29.71 Mil) but then declined from Jun. 2024 (A$29.71 Mil) to Jun. 2025 (A$22.51 Mil).


Lumos Diagnostics Holdings Total Liabilities Historical Data

* Premium members only.

The historical data trend for Lumos Diagnostics Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumos Diagnostics Holdings Total Liabilities Chart

Lumos Diagnostics Holdings Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Total Liabilities
27.12 23.72 29.71 22.51

Lumos Diagnostics Holdings Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.66 29.71 26.38 22.51 23.89
ASX:LDX
31GF Score
Lumos Diagnostics Holdings Ltd ASX:LDX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lumos Diagnostics Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Lumos Diagnostics Holdings's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=13.386+(9.124+1.7763568394003E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=22.51

Total Liabilities=Total Assets (A: Jun. 2025 )-Total Equity (A: Jun. 2025 )
=31.967-9.457
=22.51

Lumos Diagnostics Holdings's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=31.76-7.874
=23.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of A$23.89 Mil mean?
Lumos Diagnostics Holdings (ASX:LDX) has a Total Liabilities of A$23.89 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Lumos Diagnostics Holdings and its competitors.
Is Lumos Diagnostics Holdings' Total Liabilities too high?
Lumos Diagnostics Holdings' current Total Liabilities is A$23.89 Mil. Overall, Lumos Diagnostics Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumos Diagnostics Holdings' Total Liabilities compare to ABT and SYK?
Lumos Diagnostics Holdings' Total Liabilities of A$23.89 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Devices & Instruments company?
A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Lumos Diagnostics Holdings and its competitors. Lumos Diagnostics Holdings's current Total Liabilities is A$23.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (ASX:LDX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.11 — trading 425% above its estimated fair value. The current Total Liabilities is A$23.89 Mil. Lumos Diagnostics Holdings' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Lumos Diagnostics Holdings (ASX:LDX), the current Total Liabilities is A$23.89 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lumos Diagnostics Holdings (ASX:LDX) Overvalued in 2026?

Based on GuruFocus' analysis, Lumos Diagnostics Holdings stock appears to be overvalued. The current stock price of A$0.11 is trading 425% above its estimated GF Value™ of A$0.02. GuruFocus considers Lumos Diagnostics Holdings to be Significantly Overvalued.

Key valuation signals for ASX:LDX:

  • Total Liabilities: A$23.89 Mil
  • GF Value™: A$0.02 vs. price of A$0.11 (425% above fair value)
  • GF Score™: 31/100 with 7 warning signs

No single metric tells the full story. See the ASX:LDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lumos Diagnostics Holdings Business Description

Other Exchanges LDXHF:USA
Address 2724 Loker Avenue West, Carlsbad, CA, USA, 92010
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.
31GF Score

Get the complete analysis for ASX:LDX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11
Price
A$0.02
GF Value